Relevant bibliographies by topics / Hib; Meningococcal

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Hib; Meningococcal'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hib; Meningococcal.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hib; Meningococcal"

1

&NA;. "Hib vaccine/meningococcal vaccine." Reactions Weekly &NA;, no. 1284 (January 2010): 27. http://dx.doi.org/10.2165/00128415-201012840-00089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

WENDLING, PATRICE. "Hib/Meningococcal Combo Effective in Infants." Family Practice News 37, no. 12 (June 2007): 21. http://dx.doi.org/10.1016/s0300-7073(07)70734-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

WENDLING, PATRICE. "Hib/Meningococcal Combo Vaccine Effective in Infants." Pediatric News 41, no. 6 (June 2007): 1–6. http://dx.doi.org/10.1016/s0031-398x(07)70351-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Miller, Jacqueline M., Narcisa Mesaros, Marie Van Der Wielen, and Yaela Baine. "Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience." Advances in Preventive Medicine 2011 (2011): 1–17. http://dx.doi.org/10.4061/2011/846756.

Full text
Abstract:
Meningococcal diseases are serious threats to global health, and new vaccines specifically tailored to meet the age-related needs of various geographical areas are required. This paper focuses on the meningococcal conjugate vaccines developed by GSK Biologicals. Two combined conjugate vaccines were developed to help protect infants and young children in countries where the incidence of meningococcal serogroup C or serogroup C and Y disease is important: Hib-MenC-TT vaccine, which offers protection againstHaemophilus influenzaetype b andNeisseria meningitidisserogroup C diseases, is approved in several countries; and Hib-MenCY-TT vaccine, which addsN. meningitidisserogroup Y antigen, is currently in the final stages of development. Additionally, a tetravalent conjugate vaccine (MenACWY-TT) designed to help protect against four meningococcal serogroups is presently being evaluated for global use in all age groups. All of these vaccines were shown to be highly immunogenic and to have clinically acceptable safety profiles.
APA, Harvard, Vancouver, ISO, and other styles
5

Borrow, Ray, Nick Andrews, Helen Findlow, Pauline Waight, Joanna Southern, Annette Crowley-Luke, Lorraine Stapley, Anna England, Jamie Findlow, and Elizabeth Miller. "Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine." Clinical and Vaccine Immunology 17, no. 1 (November 11, 2009): 154–59. http://dx.doi.org/10.1128/cvi.00384-09.

Full text
Abstract:
ABSTRACT The kinetics of antibody persistence following the administration of a combination meningococcal serogroup C and Haemophilus influenzae type b (Hib) conjugate vaccine (Menitorix) in the second year of life in children primed with two doses of one of three monovalent meningococcal serogroup C (MCC) vaccines was investigated. The study subjects were administered either Menitorix at 12 to 15 months of age, followed by the seven-valent pneumococcal conjugate vaccine (PCV7) and the measles, mumps, and rubella vaccine 4 to 6 weeks later, or all three vaccines concomitantly at 12 to 15 months of age. Blood samples were collected before and 1, 2, 12, and 24 months after the boosting. Sera were analyzed for meningococcal serogroup C serum bactericidal antibody (SBA) and IgG as well as Hib-polyribosylribitol phosphate (PRP)-specific IgG. The antibody persistence data from this study were compared to those of a prior study of Southern et al. (Clin. Vaccine Immunol. 14:1328-1333, 2007) in which children were given three primary doses of a vaccine containing both the MCC and the Hib vaccines but were boosted only with a Hib conjugate vaccine. The magnitude of the meningococcal SBA geometric mean titer was higher for those subjects primed with the MCC vaccine conjugated to tetanus toxoid (NeisVac-C) than for those primed with one of two MCC vaccines conjugated to CRM197 (Menjugate or Meningitec) up to 1 year following boosting. Two years after boosting, the percentages of subjects with putatively protective SBA titers of ≥8 for children primed with NeisVac-C, Menjugate, and Meningitec were 43%, 22%, and 23%, respectively. Additional booster doses of the MCC vaccine may be required in the future to maintain good antibody levels; however, there is no immediate need for a booster during adolescence, as mathematical modeling has shown that persisting herd immunity is likely to control disease for a number of years.
APA, Harvard, Vancouver, ISO, and other styles
6

Schmitt, Heinz-J., Gudrun Maechler, Pirmin Habermehl, Markus Knuf, Roland Saenger, Norman Begg, and Dominique Boutriau. "Immunogenicity, Reactogenicity, and Immune Memory after Primary Vaccination with a Novel Haemophilus influenzae-Neisseria meningitidis Serogroup C Conjugate Vaccine." Clinical and Vaccine Immunology 14, no. 4 (February 7, 2007): 426–34. http://dx.doi.org/10.1128/cvi.00377-06.

Full text
Abstract:
ABSTRACT We evaluated two formulations of a new combined Haemophilus influenzae type b (Hib)-meningococcal serogroup C (MenC)-tetanus toxoid (TT) conjugated vaccine and two formulations of a new MenC-TT vaccine (trials 711202/001 and 711202/008; clinical trial register numbers NCT00135486 and NCT00135564 [www.ClinicalTrials.gov ]). A total of 520 healthy infants were randomized to receive primary vaccination (at 2, 3, and 4 months) with either MenC-TT plus diphtheria-tetanus-acellular pertussis (DTPa)-hepatitis B virus (HBV)-inactivated poliovirus (IPV)/Hib, Hib-MenC-TT plus DTPa-HBV-IPV, or MenC-CRM197 plus DTPa-HBV-IPV/Hib (control). At 12 to 15 months, subjects received a polysaccharide challenge with meningococcal polysaccharide C plus a DTPa-HBV-IPV/Hib booster. Immune responses were assessed 1 month after dose 2, 1 month after dose 3, and prior to and 1 month after the booster. After primary vaccination, there was no difference between groups in seroprotection rates as measured by titers of serum bactericidal antibody (SBA) to MenC (≥1:8) or concentrations of anti-polyribosyl ribitol phosphate (PRP) antibody (≥0.15 μg/ml). Prior to the booster, there was no difference between groups in SBA seroprotection rates, whereas anti-PRP seroprotection rates were significantly higher after priming with Hib-MenC-TT. Booster doses induced large increases in SBA and anti-PRP antibodies in primed groups, indicating successful priming with induction of immune memory. Reactogenicity and safety were similar in all groups during the primary and booster phases. A novel combined Hib-MenC-TT conjugate vaccine induced MenC and Hib responses comparable to those induced by licensed monovalent vaccines. A Hib-MenC-TT conjugate vaccine provides vaccination against two major pathogens in a single injection and is a suitable candidate for use in primary or booster vaccination schedules.
APA, Harvard, Vancouver, ISO, and other styles
7

de Voer, Richarda M., Rutger M. Schepp, Florens G. A. Versteegh, Fiona R. M. van der Klis, and Guy A. M. Berbers. "Simultaneous Detection of Haemophilus influenzae Type b Polysaccharide-Specific Antibodies and Neisseria meningitidis Serogroup A, C, Y, and W-135 Polysaccharide-Specific Antibodies in a Fluorescent-Bead-Based Multiplex Immunoassay." Clinical and Vaccine Immunology 16, no. 3 (January 7, 2009): 433–36. http://dx.doi.org/10.1128/cvi.00364-08.

Full text
Abstract:
ABSTRACT We expanded the meningococcal serogroup A, C, Y, and W-135 multiplex immunoassay (MIA) to simultaneously detect immunoglobulin type G antibodies directed toward Haemophilus influenzae type b polysaccharide (HibPS). The monoplex HibPS assay was compared to a HibPS-specific competitive enzyme-linked immunosorbent assay and showed a good correlation (R = 0.96). Furthermore, no cross-reactivity between HibPS and the four meningococcal serogroups was detected. This pentaplex meningococcal Hib MIA is a useful tool to investigate serological responses toward different childhood PS vaccines.
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Hib meningococcal groups C and Y conjugate vaccine promising." Inpharma Weekly &NA;, no. 1588 (May 2007): 7. http://dx.doi.org/10.2165/00128413-200715880-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Moss, S. J., A. C. Fenton, J. Toomey, A. Grainger, R. Borrow, P. Balmer, J. Smith, and A. R. Gennery. "Immunogenicity of a Heptavalent Conjugate Pneumococcal Vaccine Administered Concurrently with a Combination Diphtheria, Tetanus, Five-Component Acellular Pertussis, Inactivated Polio, and Haemophilus influenzae Type b Vaccine and a Meningococcal Group C Conjugate Vaccine at 2, 3, and 4 Months of Age." Clinical and Vaccine Immunology 17, no. 3 (December 30, 2009): 311–16. http://dx.doi.org/10.1128/cvi.00315-09.

Full text
Abstract:
ABSTRACT The immunogenicities of conjugate pneumococcal vaccines have been demonstrated when they are administered at 2, 3, and 4 months of age. There is a paucity of data on the immunogenicity of this vaccine when it is administered concurrently with other vaccines in the primary immunization schedule of the United Kingdom. We immunized 55 term infants at 2, 3, and 4 months of age with the seven-valent pneumococcal conjugate vaccine (PCV7), the meningococcal group C conjugate (MCC) vaccine, and the diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type b (DTaP5/IPV/Hib-TT) vaccine. The immune responses to the H. influenzae type b (Hib), MCC, and tetanus vaccines were measured at 2, 5, and 12 months of age; and the immune responses to PCV7 were measured at 2 and 5 months and then either at 12 months or following a 4th dose of PCV7. There were increases in the geometric mean concentrations (GMCs) of all antigens postimmunization. Greater than or equal to 90% of the infants achieved putatively protective levels postimmunization for all vaccine antigens except pneumococcal serotype 6B and Hib. The GMCs of the PCV7 serotypes increased following a 4th dose, although one infant had not reached putative levels of protection against serotype 6B. In conclusion, when infants were vaccinated according to the schedule described above, they had lower postprimary immunization responses to Hib, meningococcus group C capsular polysaccharide, and pneumococcal serotype 6B than the responses demonstrated by use of the other schedules. Despite this finding, there was a good response following a 4th dose of PCV7.
APA, Harvard, Vancouver, ISO, and other styles
10

Noya, Francisco, Deirdre McCormack, Donna L. Reynolds, Dion Neame, and Philipp Oster. "Safety and Immunogenicity of Two Doses of Quadrivalent Meningococcal Conjugate Vaccine or One Dose of Meningococcal Group C Conjugate Vaccine, both Administered Concomitantly with Routine Immunization to 12- to 18-Month-Old Children." Canadian Journal of Infectious Diseases and Medical Microbiology 25, no. 4 (2014): 211–16. http://dx.doi.org/10.1155/2014/237560.

Full text
Abstract:
OBJECTIVES:To describe the immunogenicity and safety of a two-dose series of a quadrivalent meningococcal (serogroups A, C, Y and W) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) administered to toddlers.METHODS: Children were randomly assigned (1:1) at study entry to receive MenACYW-D at 12 and 18 months of age (group 1; n=61) or meningococcal serogroup C conjugate vaccine (MCC) at 12 months of age (group 2; n=62). All received routine childhood immunizations. A, C, Y and W antibody titres were measured in group 1 before and one month after the 18-month MenACYW-D vaccination and were measured in group 2 at one and seven months post-MCC vaccination. Antibodies elicited by diphtheria and tetanus toxoids, and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine andHaemophilus influenzaeb conjugate (DTaP-IPV-Hib) vaccine coadministered at the 18-month vaccination were measured one month later. Safety data were collected.RESULTS: At 19 months of age, ≥96% in group 1 achieved protective titres for the four meningococcal serogroups after dose 2; 67% in group 2 exhibited protective titres against serogroup C 28 days after MCC vaccination at 12 months of age, declining to 27% seven months later. DTaP-IPV-Hib elicited high antibody concentrations/titres in groups 1 and 2, consistent with historical values. The safety profiles after each dose generated no unexpected safety signals; no serious adverse events were related to vaccination.DISCUSSION: A two-dose series of MenACYW-D given concomitantly with a DTaP-IPV-Hib booster dose at 18 months of age demonstrated a good immunogenicity and safety profile. A two-dose series of MenACYW-D can be used as an alternative to one dose of MCC and provides protection against additional serogroups (NCT ID: NCT01359449).
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hib; Meningococcal"

1

Coen, Pietro G. "Mathematical models of Haemophilus influenzae type b and Neisseria meningitidis." Thesis, University of Oxford, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.298260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Martins, Fernanda Otaviano. "Avaliação da resposta imunológica humoral, em animais de experimentação, induzida pela combinação da vacina DTP-Hib com as vacinas meningocócicas B e C conjugada, desenvolvidas em Bio-Manguinhos." Instituto de Tecnologia em Imunobiológicos, 2011. https://www.arca.fiocruz.br/handle/icict/5918.

Full text
Abstract:
Submitted by Priscila Nascimento (pnascimento@icict.fiocruz.br) on 2012-12-04T11:37:37Z No. of bitstreams: 1 fernanda-martins.pdf: 786034 bytes, checksum: e059b45f6a12387864511efbf2ecfdbe (MD5)
Made available in DSpace on 2012-12-04T11:37:37Z (GMT). No. of bitstreams: 1 fernanda-martins.pdf: 786034 bytes, checksum: e059b45f6a12387864511efbf2ecfdbe (MD5) Previous issue date: 2011
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.
A combinação de vacinas é uma estratégia de grande relevância para o Programa Nacional de Imunizações. Através dela, é possível aumentar a proteção a múltiplas doenças em uma única vacina, bem como diminuir as constantes visitas ao posto de saúde. Contudo, uma das desvantagens em relação a esse tipo de estratégia é a possibilidade de ocorrer interferência antigênica entre os seus componentes,o que pode resultar na diminuição da resposta imunológica. Devido a este fato, foi realizada uma combinação com vacinas já presentes no calendário brasileiro de imunizações (DTP-Hib) a vacinas experimentais em desenvolvimento em Bio-Manguinhos (meningocócica B e meningocócica C conjugada), com a finalidade de apresentar uma nova perspectivade produto a esta unidade bem como estabelecer a correlação antigênica entre esses componentes, comparando metodologias já padronizadas para este fim à metodologia alternativa (ELISA), além de avaliar a pirogenicidade e a interferência entre os componentes vacinais utilizados na combinação. A resposta imunológica aos componentes vacinais foiavaliada em camundongos suíços, NIH e cobaias Short-Hair pelo ELISA (VME, polissacarídeo C, PRRP, Bordetella pertussis) e os testes de soroneutralização in vivo(componentes tetânico e diftérico). Todos os componentes vacinais avaliados pelo ELISA induziram soroconversão nos animais 30 dias após a última imunização. Quando comparadas à vacina combinada completa, somente a resposta imunológica ao polissacarídeo C sofreu interferência de algum componente vacinal. Após novas combinações davacina meningocócica C conjugada às outras vacinas, pode-se concluir que avacinas DTP e Hib interagem positivamente na resposta daquela vacina. Em relação à soroneutralização in vivo, houve uma diminuição da potência dos componentes tetânicoe diftérico quando cobaias Short-Hair foram imunizadas com a vacina DTP-Hib combinada às vacinas meningocócicas B e C conjugada. Em contrapartida, na quantificação de IgG total em camundongos suíços imunizados com as duas combinações (DTP-Hib e DTP-Hib/B/C), não ocorreu diferença significativa entre os dois grupos. O teste de pirogenicidade realizado em coelhos comprovou que, quando combinadas entre si, às vacinas são capazes de aumentar a temperatura destes animais, provavelmente, devido àpresença de Bordetella pertussise VME de Neisseria meningitidisgrupo B. Apesar de não ter sido possível à comparação com ostestes padronizados, o ELISA mostrou-se muito satisfatório na pesquisa da resposta imunológica em camundongos. Embora preliminares, os resultados são muito importantes, pois introduzem novas perspectivas para a realização de outras combinações que atendam as demandas requisitadas pelo Programa Nacional de Imunizações.
The combination of vaccines is a great relevance strategy to the National Immunization Program. It enables increase protection to multiple diseases in a single injection, as well as reduces constant visits to health care. However, a disadvantage of this strategy is antigenic interference among vaccine components, resulting in immune response decreased. Due to this fact, a combination between vaccines of Brazilian immunization calendar (DTP-Hib) and experimental vaccines developed in Bio-Manguinhos (meningococcal B and meningococcal C conjugate) wasperformed, in order to present a new perspective of product to this unit and establish the antigenic correlation of these components, comparing standardized methodologies with alternative methodology (ELISA), besides evaluating pyrogenicity and interference ofcombined vaccine components. The immune response to vaccine components was evaluated in Swiss and NIH mice and Short-Hair guinea pigs by ELISA (OMV, polysaccharide C, PRP, Bordetella pertussis) and in vivoneutralization test (tetanus and diphtheria components). All vaccine components assessed by ELISA induced seroconversion rates 30 days after the last immunization in animals. The complete combined vaccine, interfered in the immune response to polysaccharide C. After new combinations of meningococcal C conjugate vaccine to other vaccines, we concluded that DTP and Hib vaccines induce a positive interaction in immune response to that vaccine. Regarding in vivoneutralization, there was a decrease of tetanus and diphtheria components potency when Short-Hair guinea pigs were immunized with DTP-Hib combined to B and C meningococcal conjugate vaccines. In contrast, when total IgG in Swiss mice immunizedwith the two combinations (DTP-Hib and DTP-Hib/B/C) was quantified, no significant difference was observed. Pirogenicity test in rabbits proved that complete combined vaccine increase the temperature of these animals, probably due to the presence of Bordetella pertussisand Neisseria meningitidisgroup B outer membrane vesicle. Although it was not possible comparision with standardized test, ELISA was a satisfactory test in studing immune response in mice. Although preliminary, the results are important because introduce new perspectives for other combinations could be done to atempt the required demands of National Immunization Program.
APA, Harvard, Vancouver, ISO, and other styles
3

Bertolini, Daniela Vinhas. "Imunogenicidade da vacina meningocócica conjugada do grupo C em adolescentes e adultos jovens com aids." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-09062014-094231/.

Full text
Abstract:
Pacientes infectados pelo HIV apresentam resposta de imunogenicidade menor àquela obtida pela população geral com a imunização de rotina. A vacina meningocócica C conjugada é indicada para essa população, não existindo pesquisas prévias que avaliassem a imunogenicidade desta, para esse grupo específico. O estudo realizou essa avaliação comparando a resposta vacinal entre os pacientes infectados e não infectados pelo HIV, as relações dessa resposta com parâmetros clínicos e laboratoriais da infecção pelo vírus e os eventos adversos à vacinação. Utilizou-se as técnicas ensaios de anticorpos bactericidas séricos ou ação bactericida no soro (SBA) e o enzyme-linked immunosorbent assay (ELISA). Tratou-se de um ensaio clínico, envolvendo 92 pacientes, com idades entre 10-20 anos, sendo 43 infectados e 49 não infectados pelo HIV. Após a vacinação, 72,1% do grupo HIV+ e 100% do grupo HIV- foram considerados protegidos. Os pacientes do grupo HIV+ não respondedores à vacinação foram revacinados, tendo sido respondedores a essa nova dose 40% destes. Portanto, 81,4% dos pacientes infectados pelo HIV adquiriram proteção com a vacina (após uma ou duas doses). Foi encontrada correlação da resposta vacinal com o número de esquemas antirretrovirais previamente utilizados e carga viral pré-vacinação, não havendo outras associações com os demais parâmetros clínicos e laboratoriais da infecção pelo HIV. Pacientes com adequada resposta vacinal tenderam a ser os de menor idade. Efeitos colaterais ocorreram em 16,3% no grupo HIV+ e em 44% no HIV-. Conclui-se que a vacina meningocócica C conjugada é segura e efetiva para uso em adolescentes e adultos jovens com aids, embora a resposta de anticorpos seja menor do que a observada em indivíduos saudáveis. Isso indica a necessidade de discussão de novos esquemas de imunização em infectados pelo HIV, objetivando uma proteção mais efetiva contra doença meningocócica
Children and adolescents infected with HIV typically have a weaker response to immunization in comparison with the healthy population. The meningococcal C conjugate vaccine is routinely recommended for those individuals. No studies, however, have evaluated the antibody response to this vaccine in HIV-infected patients yet. In this study, we compared the antibody response to the meningococcal C conjugate vaccine between HIV-infected and HIV-uninfected patients using the serum bactericidal antibody assay (SBA) and the enzyme-linked immunoabsorbent assay (ELISA). Additional objectives were to determine whether the acquired immunity correlated with clinical and laboratory features of HIV infection, and to evaluate the vaccine side effects in this population. This clinical trial included 92 patients aged 10 to 20 years old: 43 HIV-infected and 49 HIV-uninfected patients. After one single dose of the vaccine, 72.1% of the HIV-infected and 100% of the HIV-uninfected patients were considered protected. Of the HIV-infected patients (non-responders in first dose) who received a second dose of the vaccine, only 40% reached protective antibody levels. Overall, 81.4% of the HIV-infected patients reached protective antibody titres (after one or two doses of the vaccine). The antibody response in HIV-infected patients correlated with the number of prior antiretroviral therapy schedules and with the pre-vaccination viral load, but with no other clinical features or laboratory tests. Patients with adequate vaccinal response tended to be younger. Side effects occurred in 16.3% and 44% of the HIV-infected and HIV-uninfected groups, respectively. In conclusion, the meningococcal serogroup C conjugate vaccine proved to be safe and effective in HIV-infected adolescents and young adults, although their antibody response was weaker than that of HIV-uninfected patients. These results suggest that the immunization schedule for HIV-infected patients should be re-evaluated, in order to assure more effective protection against the meningococcal disease in this population
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Hib; Meningococcal"

1

Harrison, Mark. Immunological products and vaccines. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198765875.003.0046.

Full text
Abstract:
This chapter describes the pharmacology of immunological products and vaccines as they apply to Emergency Medicine, and in particular the Primary FRCEM examination. The chapter outlines the key details of active immunity, passive immunity, specific vaccines and preparations (including BCG, diphtheria, Hib, hepatitis A and B, MMR, meningococcal vaccines, pertussis, poliomyelitis, rabies, and tetanus), and immunoglobulins. This chapter is laid out exactly following the RCEM syllabus, to allow easy reference and consolidation of learning.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hib; Meningococcal"

1

Shin, Gee Yen. "Vaccination Schedules." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0062.

Full text
Abstract:
The vaccines included in the current UK Immunisation Schedule offer protection against the following pathogens: A. Viruses ● Measles ● Mumps ● Rubella ● Polio ● Human Papilloma Virus (certain serotypes) ● Rotavirus ● Influenza virus (flu A and B) ● Varicella zoster virus (shingles) ● Hepatitis B virus B. Bacteria ● Corynebacterium diphtheriae (Diphtheria) ● Clostridium tetani (Tetanus) ● Bordetella pertussis (Pertussis) ● Haemophilus influenzae type B (Hib) ● Neisseria meningitidis (Meningococcal disease—certain serotypes) ● Streptococcus pneumoniae (Pneumococcal disease—certain serotypes) The UK Immunisation Schedule has evolved over several decades and reflects changes in vaccine development and commercial availability, national and sometimes international disease epidemiology, and the latest expert opinion. It is designed to offer optimal protection against infectious diseases of childhood to infants and children at the most appropriate age. The most up-to-date information about the UK Immunisation Schedule is available on the online version of the Department of Health publication commonly known as the ‘Green Book’: Immunisation Against Infectious Disease Handbook (see Further reading. Various chapters of the online version are updated at regular intervals; thus, it is very important to refer to the online version of the Green Book on the website for current guidance. Changes to the UK Immunisation Schedule are made on the recommendation of the independent Joint Committee on Vaccines and Immunisation (JCVI). Several of the UK Immunisation Schedule vaccines are combined vaccines: ● Measles, mumps, and rubella (MMR). ● Hexavalent diphtheria, tetanus, acellular pertussis, inactivated polio virus, Haemophilus influenza type b, hepatitis B (DTaP/IPV/Hib/HepB). ● Diphtheria, tetanus, acellular pertussis, inactivated polio, and Haemophilus influenzae (DTaP/IPV/Hib). ● Diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP/IPV). ● Tetanus, diphtheria, and inactivated polio (Td/IPV). ● Inactivated influenza vaccine: influenza A H1N1, H3N2, influenza B. ● Live attenuated intranasal influenza vaccine: influenza A H1N1, H3N2, influenza B. In the UK, vaccines against single pathogens covered by the MMR vaccine are not recommended and not available in the National Health Service (NHS). There has been some limited demand for single-target vaccines, e.g. measles, due to misguided and unfounded concerns about the alleged risks of autism following MMR.
APA, Harvard, Vancouver, ISO, and other styles
2

Hadjivassiliou, Giorgos, and Edgar T. Overton. "“What shots do I need?”." In HIV, 253–58. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780190088316.003.0027.

Full text
Abstract:
This chapter reviews the current recommendations for adult persons living with HIV (PLWH) in the United States regarding vaccine-preventable diseases. In clinical practice, PLWH should be offered annual influenza vaccine; a combination of tetanus, diphtheria, and pertussis vaccine; depending on previous vaccination, pneumococcal vaccine, meningococcal conjugate vaccine, and hepatitis A and hepatitis B vaccines. Human papilloma virus vaccine can be given in PLWH up until the age of 26. Live vaccines, including the measles-mumps-rubella vaccine and varicella vaccine, can be given in those individuals who have CD4 cell counts of greater than 200 cells/mm3 and did not receive these vaccines during childhood. Some expert panels endorse recombinant zoster vaccination in PLWH at least 50 years old, although there is no current official recommendation from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. The chapter covers routine vaccinations for PLWH.
APA, Harvard, Vancouver, ISO, and other styles
3

Damani, Nizam. "Special pathogens." In Manual of Infection Prevention and Control, 338–427. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198815938.003.0009.

Full text
Abstract:
This section includes infection prevention and control (IPC) measures require for bloodborne viral infections, i.e. hepatitis B, hepatitis C, and HIV infection, gastrointestinal infections, i.e. Clostridium difficile associated diarrhoea, norovirus, and rotavirus, microorganisms spread via respiratory route, e.g. tuberculosis, influenza, respiratory syncytial virus (RSV), coronavirus (SARS and MERS-CoV), and Legionnaires’ disease. Separate parts deal with other common infections, e.g. varicella zoster virus (VZV), meningococcal infections, viral haemorrhagic fevers e.g. Lassa, Ebola, Marburg and Crimean-Congo haemorrhagic fever and human prion diseases, e.g. Creutzfeldt–Jakob disease (CJD). It also includes IPC advice on the management of scabies and infestation with lice and fleas.
APA, Harvard, Vancouver, ISO, and other styles
4

Banerjee, Ashis, Anisa J. N. Jafar, Angshuman Mukherjee, Christian Solomonides, and Erik Witt. "Infectious Diseases." In Clinical SAQs for the Final FRCEM, 151–74. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198814672.003.0011.

Full text
Abstract:
This chapter on infectious diseases contains 16 clinical Short Answer Questions (SAQs) with explanations and sources for further reading. Possible disorders and accompanying symptoms of infectious origin that may present in the emergency department include acute epiglottitis, meningitis, Ebola virus, meningococcal septicaemia, and pneumonia, among many others. It will be up to the emergency doctor to assess, diagnose, and decide upon a treatment path for each patient. The cases described in this chapter are all situations any emergency doctor is likely to encounter at some point in his or her career. The material in this chapter will greatly aid revision for the Final FRCEM examination.
APA, Harvard, Vancouver, ISO, and other styles
5

Gilsdorf, Janet R. "A Scientist and a Scientist Walk into a Bar." In Continual Raving, 223–30. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780190677312.003.0012.

Full text
Abstract:
Since Richard Pfeiffer first spotted his influenza bacilli in the respiratory secretions of patients suffering from influenza during the Russian pandemic, scientists of all stripes have built, one discovery at a time, a monument to understanding how Haemophilus influenzae, as well as pneumococci and meningococci, cause bacterial meningitis. The culmination of these many, diverse efforts is the near disappearance of this dreadful infection, at least in countries that provide vaccines to their young citizens. Earlier, smallpox, diphtheria, tetanus, whooping cough, measles, and polio became almost nonexistent in America because of a tower of scientific knowledge and the use of vaccines that emerged from that knowledge. Now, meningitis is almost there.
APA, Harvard, Vancouver, ISO, and other styles
6

Cliff, A. D., M. R. Smallman-Raynor, P. Haggett, D. F. Stroup, and S. B. Thacker. "Temporal Trends in Disease Emergence and Re-emergence: World Regions, 1850–2006." In Infectious Diseases: A Geographical Analysis. Oxford University Press, 2009. http://dx.doi.org/10.1093/oso/9780199244737.003.0019.

Full text
Abstract:
In Chapters 4–8, we have examined a series of processes that, often working in combination, have served to precipitate the emergence and re-emergence of infectious and parasitic disease agents in the human population. In this chapter, we conclude our survey with an analysis of temporal trends in disease emergence and re-emergence since 1850. The discussion is informed by long-term shifts in the underlying causes of mortality encapsulated in Omran’s model of epidemiological transition (Section 1.4.1), paying particular attention to the manner in which sample infectious and parasitic diseases have waxed and waned at a variety of geographical scales from the global to the local over the last ∼150 years. Our choice of examples strikes a balance between coverage of geographical regions and epidemiological environments, and coverage of important diseases that we have not so far examined in detail. Our consideration is structured by geographical scale: (1) At the global level, we discuss three major human diseases that have undergone phases of rapid global expansion since 1850—plague, cholera, and HIV/AIDS (Section 9.2). (2) At the regional level, we examine twentieth-century trends in general infectious disease mortality in the advanced economies of Europe, North America, and the South Pacific, 1901–75, before looking at time sequences for sample emerging (Ebola–Marburg) and cyclically re-emerging (meningococcal) diseases in sub-Saharan Africa (Section 9.3). (3) At the national level, we use Hall’s (1993) data to establish the main trends in morbidity due to infectious diseases in Australia, 1917–91 (Section 9.4). (4) At the local level, we extend our examination of long-term disease trends in London, described for the pre-1850 period in Section 2.4, into the late twentieth century (Section 9.5). The chapter is concluded in Section 9.6. In this section, we examine long-term trends in three major human infectious diseases that have undergone phases of global expansion in the last 150 years: plague (Section 9.2.1); cholera (Section 9.2.2); and HIV/AIDS (Section 9.2.3).
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hib; Meningococcal"

1

Marjuki, Henju, Nadav Topaz, Sandeep Joseph, Kim Gernert, Ellen Kersh, and Xin Wang. "O01.1 Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moe, Gregory, Peter Beernink, and Vianca Vianzon. "O01.5 A meningococcal native outer membrane vesicle vaccine as a platform for presenting conserved gonococcal antigens." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Matthias, Kathryn, Kristie Connolly, Afrin Begum, Ann Jerse, Andrew Macintyre, Gregory Sempowski, Yamei Gao, and Margaret Bash. "O01.6 Meningococcal vesicle vaccines deleted for major outer membrane proteins enhance gonococcal clearance in a murine model." In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hib; Meningococcal' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography